Steven Merlin
@stageivsurvivor.bsky.social
Stage IV survivor of pancreatic cancer diagnosed in June 2012. Underwent Whipple procedure with portal vein resection followed by aggressive chemotherapy and the first US patient enrolled in the PARP-1 inhibitor trial RucaPANC at Penn Medicine.
I’m with you Dr.Olive. I have been active on social media sites making patients/caregivers aware the current action impacting clinical research. It impacts everyone and government advocacy is needed now. I contacted members of Congress through the advocacy campaign on #PanCAN.org site & on my own.
January 25, 2025 at 10:44 PM
I’m with you Dr.Olive. I have been active on social media sites making patients/caregivers aware the current action impacting clinical research. It impacts everyone and government advocacy is needed now. I contacted members of Congress through the advocacy campaign on #PanCAN.org site & on my own.
I’ve always been a firm
believer in being proactive. Rather than wait for onset of side effects, I took anti-diarrheal and anti-emetic medications proactively to prevent symptoms leading to a better patient experience during chemo and improved quality of life.
believer in being proactive. Rather than wait for onset of side effects, I took anti-diarrheal and anti-emetic medications proactively to prevent symptoms leading to a better patient experience during chemo and improved quality of life.
January 16, 2025 at 2:51 AM
I’ve always been a firm
believer in being proactive. Rather than wait for onset of side effects, I took anti-diarrheal and anti-emetic medications proactively to prevent symptoms leading to a better patient experience during chemo and improved quality of life.
believer in being proactive. Rather than wait for onset of side effects, I took anti-diarrheal and anti-emetic medications proactively to prevent symptoms leading to a better patient experience during chemo and improved quality of life.
Now 12.5 years after a diagnosis of stage IV and the longest pancreatic cancer patient on the PARP inhibitor Rubraca for my (g)BRCA 2 mutation at 10 years 2 months.
December 6, 2024 at 11:51 PM
Now 12.5 years after a diagnosis of stage IV and the longest pancreatic cancer patient on the PARP inhibitor Rubraca for my (g)BRCA 2 mutation at 10 years 2 months.